Editorial: The evolving paradigms and treatments for primary biliary cholangitis

Aliment Pharmacol Ther. 2024 Jan;59(2):280-281. doi: 10.1111/apt.17779.

Authors

Raj Vuppalanchi¹, Kris V Kowdley²

Affiliations

¹ Division of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
² Liver Institute Northwest, Elson S. Floyd College of Medicine, Washington State University, Seattle, Washington, USA.

PMID: 38153286
DOI: 10.1111/apt.17779

No abstract available

Keywords: accelerated approval; long-term safety extension; primary biliary cholangitis; seladelpar.

Publication types

Editorial

MeSH terms

Cholangitis* / diagnosis
Humans
Liver Cirrhosis, Biliary* / diagnosis
Liver Cirrhosis, Biliary* / drug therapy
Ursodeoxycholic Acid / therapeutic use

Substances

Ursodeoxycholic Acid